Compound ID | 234
Class: Protein synthesis inhibitor
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Protein synthesis inhibitor. Targets 50S ribosomal subunit |
| Target Pathogen: | Active against Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Serratia |
| Description: | Pyrrolocytosine derivative |
| Institute where first reported: | Melinta Therapeutics, USA |
| Year first mentioned: | 2015 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| External links: | |
| Citations: |
|